<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524563</url>
  </required_header>
  <id_info>
    <org_study_id>PRO07080042</org_study_id>
    <nct_id>NCT00524563</nct_id>
  </id_info>
  <brief_title>Clinical Outcomes and Global Epidemiology -Data Coordinating Center</brief_title>
  <official_title>Clinical Outcomes and Global Epidemiology -Data Coordinating Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess for independent predictors of in-hospital mortality (up to&#xD;
      28 days) in patients with Acinetobacter bloodstream infection. Secondary Objectives include&#xD;
      the following: To determine the impact of inactive empiric antimicrobial therapy, defined as&#xD;
      receipt of empiric antimicrobial therapy with no in vitro activity against the offending&#xD;
      isolate for at least 24hrs, on the outcome (end points defined below) of patients with&#xD;
      Acinetobacter bloodstream infection. To determine the impact of carbapenem resistance and&#xD;
      pan-drug resistance (defined as resistance to all antimicrobials except colistin and/or&#xD;
      tigecycline if these agents were tested) on the outcome of patients with Acinetobacter&#xD;
      bloodstream infection. To assess the efficacy of varying definitive therapies on the outcome&#xD;
      of patients with Acinetobacter bloodstream infection. To characterize the molecular&#xD;
      epidemiology of Acinetobacter on a global level, as determined by pulsed-field gel&#xD;
      electrophoresis (PFGE) and other techniques, and to assess whether patient outcomes are&#xD;
      clonally related and to characterize the mechanisms of resistance in Acinetobacter on a&#xD;
      global scale.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medical records will be reviewed and information collected from charts to assess for&#xD;
      independent predictors of in-hospital mortality (up to 28 days) in patients with&#xD;
      Acinetobacter bloodstream infection. 24 sites will participate and all information will be&#xD;
      loaded into a password protected database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2007</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">400</enrollment>
  <condition>Acinetobacter Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        acinetobacter infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acinetobacter bloodstream infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does not meet entry criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Paterson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acinetobacter</keyword>
  <keyword>bloodstream infection</keyword>
  <keyword>Isolate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acinetobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

